Table 2.
Outcomes With First-Line Pembrolizumab Monotherapy for Patients With Advanced NSCLC, PD-L1 TPS ≥ 50%
| Outcome | All Patients (N = 441) |
|---|---|
| OS, events, n (%) | 140 (31.7) |
| Median OS (95% CI), mo | NR |
| OS rate, % (95% CI), mo | |
| At 12 | 72.2 (67.5–76.3) |
| At 24 | 57.9 (50.8–64.3) |
| Real-world PFS (rwPFS), events, n (%) | 249 (56.5) |
| Median rwPFS, (95% CI), mo | 10.0 (8.2–11.8) |
| rwPFS rate, % (95% CI) | |
| At 12 | 44.6 (39.6–49.4) |
| At 24 | 33.2 (27.7–38.8) |
| Real-world ToT (rwToT), events, n (%) | 417 (94.6) |
| Median rwToT (95% CI), mo | 5.6 (4.4–6.7) |
| On-treatment rate, % (95% CI), mo | |
| At 6 | 49.2 (44.3–53.9) |
| At 12 | 25.8 (21.7–30.1) |
| At 18 | 12.2 (9.2–15.5) |
| Real-world TTNT (rwTTNT), events, n (%) | 161 (36.5) |
| Median rwTTNT (95% CI), mo | 18.3 (14.3–NR) |
| No-next-treatment rate, % (95% CI), mo | |
| At 12 | 59.5 (54.0–64.5) |
| At 24 | 47.3 (39.6–54.6) |
CI, confidence interval; NR, not reached; OS, overall survival; rwPFS, real-world progression-free survival; rwToT, real-world time on treatment; rwTTNT, real-world time-to-next-treatment line.